glp-1 small molecule agonist A novel approach to exploit Small-Molecule glucagon-like Peptide-1 receptor agonists with high potency Orforglipron, an Oral Small-Molecule GLP-1

*Correspondence: Elisabet Jerlhag, [email protected] This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

Novo is now up to $10 billionand Pfizer has matched it, the Financial Times reported Nov

Sclerostin regulation, microarchitecture, and advanced glycation end-products in the bone of elderly women with type 2 diabetes

GLP-1R agonists effect(s) on vascular smooth muscle cells are equally important to those on endothelial cells with several favorable responses being reported, including enhanced differentiation, attenuated response to reactive oxygen species, reduced vascular remodeling through improved mitochondrial activity and dynamics, and the prevention of aberrant migration [65]